

HAPTOGLOBIN AND OTHER BIOMARKERS OF  
CORONARY ARTERY DISEASE IN YOUNG ADULTS  
WITH HYPERTENSION AND ACUTE MYOCARDIAL  
INFARCTION

BY

NORBAIYAH MOHAMED BAKRIM

A thesis submitted in fulfilment of the requirement for the degree  
of Doctor of Philosophy (Medical Sciences)

Kulliyyah of Medicine  
International Islamic University Malaysia

JUNE 2020

## ABSTRACT

Acute myocardial infarction (AMI) is the most common clinical manifestation of coronary artery disease (CAD). Young age is no longer considered a protective factor since the incidence of young adults with AMI is increasing. Hypertension is an important risk factor for CAD in young adults. Prehypertension without proper management is also associated with an increased risk of CAD. Hence, the identification of CAD biomarkers in young hypertensive and prehypertensive adults is necessary to improve risk stratification of premature AMI in these cohorts. The main objective of this study was to compare protein expression profiles of young adults with AMI to control subjects for the identification of proteins (candidate biomarkers) that are differentially expressed in AMI patients. This study also aimed to determine the plasma concentrations of the candidate biomarkers in young adults with normotension, prehypertension, hypertension and AMI and evaluate the relationship between AMI and potential CAD biomarker/s in young hypertensive and prehypertensive subjects. This study comprised of two phases; discovery and verification. In the discovery phase, proteins in the pooled plasma samples from young male adults (10 AMI patients and 10 controls) aged 18 to 45 years were separated by two-dimensional gel electrophoresis (2-DE). The protein spots that were differentially expressed in AMI patients relative to the controls were identified via matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry. In the verification phase, the plasma concentrations of the identified proteins were measured using enzyme-linked immunosorbent assay (ELISA) in 40 plasma samples of control, prehypertensive, hypertensive and AMI groups. In the discovery phase, haptoglobin (Hp), apolipoprotein AI (Apo AI) and apolipoprotein AIV (Apo IV) were significantly upregulated in AMI patients in comparison to the controls ( $p < 0.05$ ). Meanwhile in the verification phase, the plasma concentration of Hp was significantly higher in AMI patients in comparison to the control, prehypertensive and hypertensive subjects ( $290.63 \pm 99.90$  vs.  $170.02 \pm 108.11$  vs.  $175.05 \pm 108.11$  and vs.  $208.47 \pm 112.97$  ng/ml,  $p < 0.006$ ) respectively. The plasma concentrations of Apo AI and Apo AIV were also elevated in AMI patients, yet the increases were not significant compared to the other groups ( $p > 0.05$ ). Plasma concentration of Hp was significantly associated with young AMI (OR: 1.019, 95% CI: 1.006-1.033,  $p = 0.003$ ) after adjusting for other known CAD risk factors. There was also a significant association between AMI and plasma concentration of Hp in hypertensive and prehypertensive subjects (OR: 0.985, 95% CI: 0.973-0.997,  $p = 0.017$  and OR: 0.981, 95% CI: 0.969-0.993,  $p = 0.002$ ) respectively, independent of other known CAD risk factors. Plasma Hp concentration was significantly correlated with high sensitivity C-reactive protein hs-CRP ( $r = 0.370$ ,  $p < 0.001$ ). In Conclusion, consistent upregulation of Hp in discovery and verification phases reflect its potential role as a biomarker of CAD in young adults. Hp is also a potential CAD biomarker that could be utilized as AMI predictor in young adults with hypertension and prehypertension. The significant correlation between Hp and hs-CRP indicates the potential role of these proteins as inflammatory markers in the establishment of CAD in young adults.

## خلاصة البحث

فشل قلبي حاد هي المظاهر السريرية الأكثر شيوعاً لمرض القلب التاجي . لم يعد السن مبكراً عاملاً وقائياً حيث تزداد نسبة الإصابة بالشباب البالغين المصابين بفشل قلبي حاد. تم تحديد ارتفاع ضغط الدم كعامل خطر مهم في تطوير مرض القلب التاجي في سن مبكرة. يرتبط ارتفاع ضغط الدم دون إدارة مناسبة أيضاً بزيادة خطر الإصابة بمرض القلب التاجي. وبالتالي ، فإن تحديد العلامات البيولوجية لمرض القلب التاجي في البالغين الصغار ارتفاع ضغط الدم وما قبل ارتفاع ضغط الدم ضروري لتحسين التنبؤ بفشل قلبي حاد في هذه الأوج. تم اقتراح التحليل البروتيني باعتباره أفضل طريقة في تحديد العلامات البيولوجية في الأمراض متعددة العوامل مثل مرض القلب التاجي. الهدف: كان الهدف الأول من هذه الدراسة هو مقارنة ملامح التعبير البروتين من الشباب البالغين مع فشل قلبي حاد للسيطرة على الموضوعات لتحديد العلامات البيولوجية المرشحة التي يتم التعبير عنها بشكل مختلف في المرضى فشل قلبي حاد. كان الهدف الثاني هو تحديد تركيزات البلازما الخاصة بالعلامات البيولوجية في البالغين الصغار المصابين بالضغط الطبيعي وارتفاع ضغط الدم وما قبل ارتفاع ضغط الدم وفشل قلبي حاد لتقييم العلاقة بين فشل قلبي حاد والعلامة البيولوجية لمرض القلب التاجي المحتمل في موضوعات ارتفاع ضغط الدم وما قبل ارتفاع ضغط الدم. الطريقة: تتألف هذه الدراسة على مرحلتين: الاكتشاف والتحقق. في مرحلة الاكتشاف ، تم فصل البروتينات في عينات البلازما المجمعة من الشباب البالغين (١٠ مرضى فشل قلبي حاد و ١٠ عناصر تحكم) تتراوح أعمارهم بين ١٨ إلى ٤٥ عاماً بواسطة جهاز الفصل الكهربائي ثنائي الأبعاد. تم تحديد بقع البروتين التي بواسطة المصفوفة. في مرحلة التحقق ، تم قياس تركيزات البلازما للبروتينات المحددة باستخدام مقياس الإمتصاص المناعي في ٤٠ عينة من البلازما للتحكم ، ارتفاع ضغط الدم وما قبل ارتفاع ضغط الدم ، ومرضى فشل قلبي حاد. النتائج: في مرحلة الاكتشاف ، تم تنظيم هابتوغلوبين ، أبوليوبروتين AI ، وأبوليوبروتين AIV بشكل كبير في مرضى فشل قلبي حاد مقارنة بعناصر التحكم (ع احتشاء فشل قلبي حاد هي المظاهر السريرية الأكثر شيوعاً لمرض القلب التاجي). لم يعد السن مبكراً عاملاً تم التعبير عنها تفاضلياً في مرضى فشل قلبي حاد بالنسبة لعناصر التحكم من خلال قياس الطيف الكتلي للرياح / التأين بالليزر المدعم وقائياً حيث تزداد نسبة الإصابة بالشباب البالغين المصابين بفشل قلبي حاد. تم تحديد ارتفاع ضغط الدم كعامل خطر مهم في تطوير مرض القلب التاجي في سن مبكرة. يرتبط ارتفاع ضغط الدم < ٠,٠٥. بينما في مرحلة التحقق ، كان تركيز البلازما ل هابتوغلوبين أعلى بشكل ملحوظ في مرضى فشل قلبي حاد. مقارنةً بالمواضيع السابقة لارتفاع ضغط الدم وما قبل ارتفاع ضغط الدم (٢٩٠,٦٣ ± ٩٩,٩٠ مقابل ١٧٥,٠٢ ± ١٠٨,١١ مقابل ١٧٥,٠٥ ± ١٠٨,١١ و مقابل ٢٠٨,٤٧ ± ١١٢,٩٧ / ng / مل ، ع > ٠,٠٠٦) على التوالي. كانت تركيزات البلازما من أبوليوبروتين AI و أبوليوبروتين AIV مرتفعة أيضاً في مرضى فشل قلبي حاد ، لكن الزيادات لم تكن كبيرة مقارنة بالمجموعات الأخرى (ع = ٠,٣٢ و ع = ٠,٩٥٧). ارتبط تركيز البلازما ل هابتوغلوبين بشكل كبير مع فشل قلبي حاد الشباب (نسبة الأرجحية: ١,٠١٩، مجال الثقة: ١,٠٠٦ - ١,٠٣٣ ، ع = ٠,٠٠٣) بعد التعديل لعوامل الخطر المعروفة الأخرى لفشل قلبي حاد. كان هناك أيضاً ارتباط مهم بين فشل قلبي حاد وتركيز البلازما ل هابتوغلوبين في موضوعات ارتفاع ضغط الدم وخافضة الضغط (نسبة الأرجحية: ٠,٩٨٥ ، ع = ٠,١٧ ، مجال الثقة: ٠,٩٧٣ - ٠,٩٩٧ ، ٩٥٪ ، ع = ٠,٠١٧ ونسبة الأرجحية: ٠,٩٨١ ، مجال الثقة: ٠,٩٦٩ - ٠,٩٩٩ ، ٩٥٪ ، ع = ٠,٠٠٢) على التوالي ، مستقلة عن عوامل الخطر المعروفة الأخرى. ارتبط تركيز البلازما هابتوغلوبين بشكل كبير مع حساسية عالية من البروتين سي التفاعلي (ع = ٠,٣٧٠ ، ع < ٠,٠٠١). الخلاصة: يعكس الانتظام المنسق ل هابتوغلوبين في مراحل الاكتشاف والتحقق دورها المحتمل كمؤشر حيوي لتطوير مرض القلب التاجي في الشباب. تعد هابتوغلوبين أيضاً علامة بيولوجية لمرض القلب التاجي محتملة يمكن استخدامها في تحديد البالغين المصابين بارتفاع ضغط الدم وما قبل ارتفاع ضغط الدم ، والذين يتعرضون لخطر كبير من الإصابة بتطوير مرض القلب التاجي. يشير الارتباط الهام بين هابتوغلوبين والبروتين سي التفاعلي إلى الدور الهام للمسارات الالتهابية في إنشاء مرض القلب التاجي عند البالغين الصغار.

## **APPROVAL PAGE**

The thesis of Norbaiyah Mohamed Bakrim has been approved by the following:

---

Aszrin Abdullah  
Supervisor

---

Norlelawati A. Talib  
Co-Supervisor

---

Jamalludin Ab Rahman  
Co-Supervisor

---

Noraslinda Muhammad Bunnori  
Co-Supervisor

---

Abdul Razak Kasmuri  
Internal Examiner

---

Abdul Latiff Mohamed  
External Examiner

---

Rafidah Hanim Mokhtar  
External Examiner

---

Ahmad Aidil Arafat Zulkarnain  
Chairman

## **DECLARATION**

I hereby declare that this thesis is the result of my own investigation, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Norbaiyah Mohamed Bakrim

Signature.....

Date .....

**INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA**

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF  
FAIR USE OF UNPUBLISHED RESEARCH**

**HAPTOGLOBIN AND OTHER BIOMARKERS OF CORONARY  
ARTERY DISEASE IN YOUNG ADULTS WITH HYPERTENSION  
AND ACUTE MYOCARDIAL INFARCTION**

I declare that the copyright holder of this thesis is International Islamic University  
Malaysia

Copyright © 2020 by International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below.

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieval system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Norbaiyah Mohamed Bakrim

.....  
Signature

.....  
Date

## ACKNOWLEDGEMENT

*Alhamdulillah*, all praises be to Allah under whose blessing and guidance that has made it possible for me to complete this PhD journey. He provided me with the opportunity to have worked with great and helpful people who have contributed in various ways to my PhD work that deserve special mention.

First and foremost, I wish to acknowledge my parents, Hj Mohamed Bakrim Bin Sani and Hjh Siti Rohaniah Marzuki who raised me up to be able to reach this level. My parents-in-law; Dr. Hj Alias Othman and Hjh Naaimah Ramli who have shown their support and understanding of my decision to undertake this journey. The greatest appreciation to my supportive and respected husband; Dr. Mohd Afzal Alias who has been my backbone, source of motivation and courage, to keep me moving forward during the ups and downs of research. To my beloved children, Ameerul Muttaqeen, Taufeeq Muttaqeen, Himmah Aleeyah, Dzatiyah Aleeyah and my PhD baby, Thoreeq Muttaqeen - thank you for being the main reason for me to keep going despite any difficulties I faced. I hope my perseverance would inspire all of you to be the best in anything that you do in the future.

Secondly, it was not possible for this work to come to light in this form, without the experience and confident guidance of my supervisor Asst. Prof. Dr. Aszrin Abdullah, who has shown constant interest, wholehearted commitment and pain staking supervision to ensure this research was conducted competently. Thank you Dr Aszrin, for the *qudwah*, mentorship and sisterly bonding that always inspire me to give the best as a student. My heartfelt gratitude goes to my experienced co-supervisor Assoc. Prof. Dr. Norlelawati A. Talib, for her endless assistance and essential guidance to ensure the best outcome for the study. I am also greatly indebted to all other experts in the supervisory team; Prof. Dr. Azarisman Shah Mohd Shah for his valuable clinical insight, Assoc. Prof. Dr. Jamalludin bin Ab Rahman for his enlightening statistical input, Asst. Prof. Dr. Noraslinda Muhammad Bunnori for her comprehensive guidance in proteomic and Asst. Prof. Dr. Aida Sharini Mohd Shah for her assistance in facilitating the recruitment of patients. My deepest gratitude to En Yusri Idorus, the Researcher Officer of Proteomic Laboratory at Institute of Medical Molecular Biotechnology (IMMB) UiTM Sungai Buloh for his important role as an advisor for the proteomic laboratory works. As a beginner, I was so fortunate to have him as a very helpful and skillful assistant.

A great deal of credit goes to Prof. Dr Mohd Azmi Md Nor (Dean on Kulliyyah of Medicine), Prof. Dr Imad Deen (Head of Department of Basic Medical Sciences) for their role in providing constructive advices and technical support in completion of my PhD. My greatest appreciation flows to all the helpful lecturers and staff at Department of Basic Medical Sciences (Kulliyyah of Medicine) who contributed their knowledge and experiences in improving my work. I would like to thank the Director of the Hospital Tengku Ampuan Afzan (HTAA), the Head and the staff of Emergency Department and Cardiology Department of HTAA and Jabatan Kesihatan Negeri Pahang for allowing me to use their facilities for subjects recruitment. I would also like to thank the IIUM Research Management Centre for the research initiative grant scheme (RIGS 15-076-0076) and Ministry of Education, Malaysia for the Fundamental Research Grant Scheme (FRGS 16-056-0555) to finance the study.

Last, but not least, my utmost appreciation to all my other family members and friends for all their support and prayers. I wish this piece of work will be beneficial to the *ummah* and will encourage other great work in the future.

# TABLE OF CONTENTS

Abstract .....	ii
Abstract in Arabic .....	iii
Approval Page.....	iv
Declaration.....	v
Acknowledgement .....	vii
Table of Contents .....	viii
List of Tables .....	xii
List of Figures .....	xiv
List of Abbreviations .....	xvii
<b>CHAPTER ONE: INTRODUCTION .....</b>	<b>1</b>
1.1 Background and Justification of Research .....	1
1.2 Problem Statement.....	7
1.3 Research Question .....	9
1.4 Research Objectives.....	9
1.4.1 General Objective.....	9
1.4.2 Specific Objectives.....	9
1.5 Research Hypothesis.....	10
1.6 Conceptual Framework.....	11
<b>CHAPTER TWO: LITERATURE REVIEW.....</b>	<b>12</b>
2.1 Overview of Coronary Circulation .....	12
2.2 Coronary Artery Disease .....	17
2.2.1 Definition of Acute Myocardial Infarction.....	17
2.3 AMI in Young Adults .....	17
2.3.1 Prevalence of AMI in Young Adults .....	17
2.3.2 Definition of ‘Young Adults’ .....	19
2.3.3 Young Adults with AMI in Malaysia .....	23
2.3.4 Risk Factor Profiles of Young Adults with AMI.....	24
2.4 Hypertension and Prehypertension in Young Adults .....	29
2.4.1 Definition of Hypertension and Prehypertension.....	29
2.4.2 Epidemiology of Hypertension and Prehypertension in Young Adults.....	32
2.4.3 Current Management of Hypertension and Prehypertension .....	34
2.5 Pathophysiology of Coronary Artery Disease .....	36
2.5.1 Pathogenesis of CAD in Young Adults .....	39
2.6 Proteomic Analysis of Coronary Artery Disease.....	40
2.6.1 Proteomic Analysis of the Atherosclerotic Plaque.....	43
2.6.2 Proteomic Analysis of Human Plasma.....	45
2.6.3 Plasma Proteomic Biomarkers in CAD .....	47
2.6.4 Plasma Proteomic Biomarkers in Young CAD.....	50
2.6.5 High Sensitivity C-reactive protein (Hs-CRP).....	52
2.6.6 Biomarkers to Predict CAD in Hypertensive Patients .....	54
2.7 Chapter Summary .....	55



<b>CHAPTER THREE: METHODOLOGY.....</b>	<b>57</b>
3.1 Study Design.....	57
3.2 Study Period .....	57
3.3 Ethical Approval.....	58
3.4 Determination of Sample Size .....	58
3.5 Subjects Recruitment and Sample Collection.....	59
3.5.1 Recruitment of Young Patients with AMI and Sample Collection..	60
3.5.1.1 Inclusion Criteria for AMI Patients .....	60
3.5.1.2 Exclusion Criteria for AMI Patients .....	60
3.5.1.3 Urine and Blood Sample Collection of AMI Patients .....	61
3.5.1.4 Blood Sample Processing and Storage .....	61
3.5.1.5 Socio-demographic, CVD Risk Factors and Biochemical Data Collection.....	62
3.5.2 Recruitment of Normal, Prehypertensive and Hypertensive Subjects.....	62
3.5.2.1 Inclusion Criteria for Control, Prehypertensive and Hypertensive Subjects .....	63
3.5.2.2 Exclusion Criteria for Control, Prehypertensive and Hypertensive Subjects .....	63
3.5.2.3 Blood Pressure Measurement .....	64
3.5.2.4 Blood Sample Collection.....	65
3.5.2.5 Blood Sample Processing and Storage .....	65
3.5.2.6 Socio-demographic Data and CVD Risk Factor Profiles .....	65
3.5.3 Study Flow Chart .....	66
3.6 Confidentiality and Privacy .....	67
3.7 Discovery Phase.....	68
3.7.1 Samples Pooling.....	68
3.7.2 Albumin Removal Procedure .....	69
3.7.2.1 Materials for Albumin Removal Procedure .....	69
3.7.2.2 Method for Albumin Removal Procedure .....	69
3.7.3 One-Dimensional Electrophoresis .....	71
3.7.3.1 Preparation of Running Buffer, Stacking and Resolving Gels.....	71
3.7.3.2 Method for Assembling and Running of 1-DE .....	72
3.7.4 Preparation of Plasma Samples for 2-DE.....	73
3.7.4.1 Materials for Plasma Clean up .....	73
3.7.4.2 Method for Plasma Clean up and Preparation for 2-DE.....	74
3.7.5 Two-Dimensional Electrophoresis (2-DE) .....	77
3.7.5.1 Materials for 2-DE.....	77
3.7.5.2 Method for 2-DE .....	78
3.7.5.2.1 Sample Preparation for Rehydration .....	78
3.7.5.2.2 Sample Application during Rehydration.....	78
3.7.5.3 First Dimension of 2-DE: Isoelectric Focus Point (IEF).....	79
3.7.5.3.1 Preparation of Equilibration Buffer I and II.....	81
3.7.5.3.2 IPG Strips Equilibration .....	81
3.7.5.4 Second Dimension of 2-DE: Protein Separation by SDS- PAGE .....	82

3.7.6 Gels Staining with Coomassie Brilliant Blue R-250 Stain. ....	84
3.7.6.1 Materials for Gel Staining .....	84
3.7.6.2 Method for Gel Staining.....	84
3.7.7 Analysis of Two-Dimensional Gel Images using PD Quest Software.....	86
3.7.8 Identification of Proteins by MALDI-TOF MS.....	87
3.8 Verification Phase.....	88
3.8.1 Determination of Plasma Concentrations of Hp, Apo AI and Apo AIV .....	88
3.8.1.1 Materials for ELISA Analysis .....	88
3.8.1.2 Method for ELISA Analysis.....	89
3.8.1.2.1 Preparation of the Reagent.....	89
3.8.1.2.2 Assay Procedure.....	91
3.8.1.2.3 Calculation of Plasma Protein Concentration .....	93
3.9 Statistical Analysis.....	94
<b>CHAPTER FOUR: RESULTS AND FINDINGS.....</b>	<b>95</b>
4.1 Baseline Characteristics of Study Participants .....	95
4.1.1 Subjects in Discovery Phase .....	95
4.1.1.1 Socio-Demographic Characteristics and CVD Risk Factor Profiles .....	95
4.1.1.2 Clinical Presentation.....	97
4.1.2 AMI Patients in Verification Phase .....	98
4.1.2.1 Socio-Demographic Characteristics and CVD Risk Factor Profiles .....	98
4.1.2.2 Clinical Presentation.....	102
4.1.3 Comparison of Baseline Characteristics in All Groups .....	104
4.2 Proteomic Profiling.....	108
4.2.1 One-Dimensional Electrophoresis (1-DE).....	108
4.2.2 Two-Dimensional Electrophoresis (2-DE) .....	109
4.2.3 Differential Proteomic Profiles Analysis .....	112
4.2.4 Identification of Protein Spots by MALDI-TOF MS.....	113
4.3 Plasma Concentrations of Hp, Apo AI and Apo AIV .....	116
4.3.1 ELISA Standard Curves.....	116
4.3.2 Plasma Concentrations of Haptoglobin.....	119
4.3.3 Plasma Concentrations of Apolipoprotein A1 .....	120
4.3.4 Plasma Concentration of Apolipoprotein AIV.....	121
4.4 Relationship between Plasma Concentration of Haptoglobin and AMI in Young Adults .....	122
4.4.1 Relationship between AMI and Plasma Concentrations of Haptoglobin in Prehypertensive and Hypertensive Subjects.....	123
4.5 Correlation between Haptoglobin and hs-CRP .....	125
<b>CHAPTER FIVE: DISCUSSION .....</b>	<b>126</b>
5.1 Overview of the Study Findings .....	126
5.2 Socio-Demographic, CVD Risk Factors and Clinical Presentation of Study Participants .....	128
5.2.1 Young Adults with Acute Myocardial Infarction .....	128
5.2.1.1 Socio-Demographic Characteristics .....	128

5.2.1.2 CVD Risk Factor Profiles.....	129
5.2.1.3 Clinical Presentation.....	131
5.2.2 Young Adults with Hypertension .....	132
5.2.3 Young Adults with Prehypertension .....	133
5.3 Candidate Biomarkers of CAD in Young Adults .....	135
5.3.1 Haptoglobin.....	135
5.3.2 Apolipoprotein AI.....	137
5.3.3 Apolipoprotein AIV .....	140
5.4 Verification of Candidate Biomarkers.....	143
5.4.1 Plasma Concentration of Candidate Biomarkers in AMI Patients. ....	143
5.5 The Role of Haptoglobin to Predict CAD in Young Prehypertensive and Hypertensive Adults .....	145
5.6 Correlation between Haptoglobin and hs-CRP .....	148
5.7 Clinical Implications of the Findings .....	149
5.7.1 Early CVD Risk Factors Screening among Young Adults .....	149
5.7.2 Effective Blood Pressure Control among Young Hypertensive and Prehypertensive Adults .....	150
5.7.3 Haptoglobin as a New Biomarker to Predict CAD in Young Adults .....	151
5.7.4 Targeting Inflammatory Pathway to Reduce CAD Risk .....	152
5.8 Strengths and Limitations of the study .....	153
<b>CHAPTER SIX: CONCLUSION.....</b>	<b>155</b>
<b>REFERENCES.....</b>	<b>157</b>
<b>APPENDIX II: LIST OF PRESENTATIONS .....</b>	<b>179</b>
<b>APPENDIX III: ETHICAL APPROVALS .....</b>	<b>184</b>
<b>APPENDIX IV: PATIENT INFORMATION SHEET .....</b>	<b>190</b>
<b>APPENDIX V: INFORMED CONSENT FORM.....</b>	<b>194</b>
<b>APPENDIX VI: RISALAH MAKLUMAT PESERTA KAJIAN .....</b>	<b>196</b>
<b>APPENDIX VII: BORANG PERSETUJUAN PESERTA .....</b>	<b>201</b>
<b>APPENDIX VIII: CASE REPORT FORM .....</b>	<b>203</b>

## LIST OF TABLES

Table 2.1	Third Universal Definition of acute myocardial infarction.	14
Table 2.2	Epidemiological studies of acute myocardial infarction in young adults.	20
Table 2.3	Age group of AMI patients who underwent PCI from 2013 till 2016.	23
Table 2.4	Framingham cardiovascular risks score for men.	24
Table 2.5	Studies on risk factor profiles of acute myocardial infarction in young adults.	25
Table 2.6	Risk factors for young and elderly with AMI in Malaysia.	28
Table 2.7	Classification of blood pressure according to JNC 7.	30
Table 2.8	Advantages and disadvantages of proteomic techniques.	42
Table 2.9	Plasma proteomic studies reporting potential proteomic CAD biomarkers.	48
Table 3.1	List of recruitment sites.	59
Table 3.2	Reagents for preparation of 1X Tris/glycine (TGS) running buffer.	71
Table 3.3	Reagents for preparation of stacking and resolving gel.	72
Table 3.4	Three-step protocol for isoelectric focus points.	80
Table 3.5	Reagents for preparation of Equilibrium Buffer I and II.	81
Table 3.6	Reagents for preparation of 12 % resolving gels.	82
Table 3.7	Serial dilution of standard working solution for ELISA.	90
Table 4.1	Baseline characteristics of all subjects in the discovery phase.	96
Table 4.2	Clinical presentation of young adults with AMI.	103
Table 4.3	Baseline characteristics of all subjects in the verification phase.	106

Table 4.4	Proteins that were differently expressed in young adults with AMI in comparison to the controls as identified by MALDI TOF MS.	115
Table 4.5	Association between haptoglobin and AMI.	122
Table 4.6	Association between haptoglobin in prehypertensive and hypertensive subjects and AMI.	124

## LIST OF FIGURES

Figure 1.1	Conceptual framework.	11
Figure 2.1	The coronary blood vessels.	12
Figure 2.2	Risk stratifications for cardiovascular major events in 10 years according to blood pressure.	35
Figure 2.3	Pathophysiological links between hypertension and coronary artery disease.	38
Figure 2.4	Procedures of plasma proteomic profiling using two-dimensional electrophoresis (2-DE).	46
Figure 3.1	Study design.	57
Figure 3.2	Flow chart of subject recruitment for all groups and sample collection.	66
Figure 3.3	Stacking and resolving gel for one-dimensional of sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) analysis.	73
Figure 3.4	The extracted protein sample at the end of clean up procedure (white pallet).	76
Figure 3.5	Electrophoresis using a PROTEAN IEF cell (Bio Rad)	80
Figure 3.6	Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).	83
Figure 3.7	Gel scanning using UMAX POWERLOOK 1000 image scanner.	85
Figure 3.8	Scheme describing analysis gel images using PD Quest Version 2.7.0 image analysis software.	86
Figure 3.9	Representative diagram of dilution method for reference standard of haptoglobin protein.	90
Figure 3.10	Enzyme-linked immunosorbent assay (ELISA) plate wells containing protein-antibody-HRP conjugate complex and	92

substrate solution.

Figure 3.11	Enzyme-linked immunosorbent assay (ELISA) plate wells as the enzyme-substrate reaction was ceased.	93
Figure 4.1	Age distribution of young adults with acute myocardial infarction.	98
Figure 4.2	Racial differences of young adults with acute myocardial infarction.	99
Figure 4.3	Household income distribution of young adults with acute myocardial infarction.	100
Figure 4.4	Type of occupations of young adults with acute myocardial infarction	100
Figure 4.5	Cardiovascular risk factor profiles of young adults with acute myocardial infarction	101
Figure 4.6	One-dimensional (1-D) of sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) analysis	108
Figure 4.7	Two-dimensional electrophoresis (2-DE) gel image of protein map in control plasma using a pH range 3 to 10	109
Figure 4.8	Two-dimensional electrophoresis (2-DE) gel images of plasma from patients with acute myocardial infarction (AMI) and age-matched control subjects using a pH range 4 to 7 (Set 1).	110
Figure 4.9	Two-dimensional electrophoresis (2-DE) gel images of plasma from patients with acute myocardial infarction (AMI) and age-matched control subjects using a pH range 4 to 7 (Set 2).	111
Figure 4.10	Two-dimensional electrophoresis (2-DE) gel images of plasma from patients with acute myocardial infarction (AMI) and age-matched control subjects (Set 3) using a pH range 4 to 7 (Set 3).	111
Figure 4.11	Representative of two-dimensional electrophoresis (2-DE) gel image showing the location of protein spots that were expressed differently ( $p < 0.05$ ) in AMI patients in comparison to the controls using Independent Student's T-test as analysed by PD Quest 7.2.0 Software.	112
Figure 4.12	Representative patterns of protein spots SSP 2501, SSP 1601 and SSP 7201.	113

Figure 4.13	Peptide mass spectra of <b>A</b> (SSP 2501), <b>B</b> (SSP 1601), and <b>C</b> (SSP 7201) as per Matrix-assisted Laser Desorption/Ionization Time of Flight (MALDI-TOF) mass spectrometry analysis.	114
Figure 4.14	Graph of standards for haptoglobin.	116
Figure 4.15	Graph of standards for apolipoprotein AI.	117
Figure 4.16	Graph of standards for apolipoprotein AIV.	118
Figure 4.17	Plasma concentration of haptoglobin.	119
Figure 4.18	Plasma concentration of apolipoprotein AI.	120
Figure 4.19	Plasma concentration of apolipoprotein AIV.	121
Figure 4.20	Plasma concentration of hs-CRP.	125
Figure 5.1	Haptoglobin protein structure.	135
Figure 5.2	Apolipoprotein AI (Apo AI) protein structure.	138
Figure 5.3	Apolipoprotein AIV (Apo AIV) protein structure.	141



## LIST OF ABBREVIATIONS

ACS	Acute coronary syndrome
AMI	Acute myocardial infarction
Apo AI	Apolipoprotein AI
Apo AIV	Apolipoprotein AIV
APS	Ammonium persulfate
BMI	Body mass index
CAD	Coronary artery disease
CABG	Coronary artery bypass surgery
CI	Confidence interval
CK-MB	Creatinine kinase-myocardial band
CRF	Case record form
CTU	Clinical trial unit
CVD	Cardiovascular disease
DBP	Diastolic blood pressure
1-DE	One-Dimensional electrophoresis
2-DE	Two-Dimensional electrophoresis
ECG	Electrocardiography
ELISA	Enzyme-linked immunosorbent assay
EDTA	Ethylenediaminetetraacetic acid
FBS	Fasting blood sugar
HCl	Hydrochloric acid
HDL	High density lipoprotein
Hs-CRP	High sensitivity C-reactive protein
Hs-cTn	High sensitivity cardiac troponin
HTAA	Hospital Tengku Ampuan Afzan
Hp	Haptoglobin
HRP	Horseradish Peroxidase
IEF	Iso electric focus

IPG	Immobilized pH gradient
iTRAQ	Isobaric tags for relative and absolute quantification
JNC	Joint National Committee
kDa	Kilodalton
LDL	Low density lipoprotein
mRNA	Messenger RNA
mmHg	Milimetre per mercury
MALDI TOF	Matrix-assisted laser desorption/ionization-time of flight
MOH	Ministry of Health
MS	Mass spectrometry
mM	Milimolar
ml	Mililitre
MREC	Medical Review and Ethics Committee
NCVD	National Cardiovascular Database
NMRR	National Medical Research Register
NHMS	National Health and Morbidity Survey
NSTEMI	Non-ST Elevated myocardial infarction
OD	Optical density
OR	Odd ratio
PCI	Percutenous coronary intervention
RR	Relative risk
SBP	Systolic blood pressure
SDS PAGE	Sodium dodecyl supfate polyacrylamide gel eletrophoresis
SMCs	Smooth muscle cells
STEMI	ST-elevated myocardial infarction
TC	Total cholesterol
TEMED	Tetramethylenediamine
USD	United State Dolar
vCAM-1	Vascular cell adhesion molecule 1
Vs.	Versus
WHO	World Health Organization

# **CHAPTER ONE**

## **INTRODUCTION**

### **1.1 BACKGROUND AND JUSTIFICATION OF RESEARCH**

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality that accounts for almost one third of deaths worldwide. In the United States, approximately 2200 Americans die of CVD each day, roughly one death in every 40 seconds (Mozaffarian, Benjamin, Go, Arnett, Blaha, Cushman, et al., 2016). The healthcare cost to manage CVD was about USD\$ 272 billion (approximately RM 1132 billion) in 2010 and estimated to triple to USD\$ 818 billion (approximately RM 3405 billion) in 2030 (Tran, Ohinmaa, Thanh, & Welsh, 2017). Unfortunately, nowadays CVD is not merely a disease in developed communities, but it has also affected developing countries. In fact, Southeast Asia was predicted to have the highest percentage increase in CVD-related deaths by 2030 (World Health Organization [WHO], 2017).

In Malaysia, CVD is the most common cause of death and accounted for 23% of total hospital mortality (Ministry of Health, 2015). The most prevalent CVD is coronary artery disease (CAD), specifically acute coronary syndrome (ACS) which includes acute myocardial infarction (AMI) and angina. The hospitalisation cost for AMI patient requiring percutaneous coronary intervention (PCI) is approximately RM 12,117 in public hospitals and RM 16,289 in teaching hospitals (Lee, Azman, Ahmad, Low, Liau, Anchah, et al., 2017). The economic burden due to AMI is expected to increase as the prevalence of AMI is shifting to younger Malaysian adults. The mean age of AMI patients in Malaysia is 58 years old (Wan Ahmad, 2017), about seven

years younger compared to AMI patients in general populations (Sorbetes, Greenlaw, Ferrari, Ford, Fox, Michal, et al., 2017).

It is an established fact that an increasing age is a non modifiable risk factor for AMI (Agostino, Vasan, Pencina, Wolf, Cobain, Massaro, et al., 2008; Hajar, 2017). Unfortunately, young age is no longer protective as the incidence of AMI in young adults is currently increasing. Over the past four decades, there has been a decline in AMI admissions among the general population (Bhatnagar, Wickramasinghe, Wilkins, & Townsend, 2016). However, there has been no concomitant reduction in AMI admissions for patients below the age of 55 (Gupta, Wang, Spertus, Geda, Lorenze, Nkonde-Price, et al., 2014). The reported incidence of young patients diagnosed with AMI varied from 3% to 10% in high income populations, and 10% to 20% of total CAD admissions in low to middle income populations (Joshi, Islam, Pais, Reddy, Dorairaj, Kazmi, et al., 2007; Shah, Kelly, Cox, Wong, & Soon, 2016).

According to the Malaysia National Cardiovascular Disease Database (NCVD) Registry Report from 2007 to 2009, approximately 16% of the AMI patients who underwent PCI in tertiary hospitals were less than 45 years for male and 55 years for female (Zuhdi, Mariapun, Mohd Hairi, Wan Ahmad, Abidin, Undok, et al., 2013). A more recent NCVD-PCI Registry in 2016 reported the percentage of AMI patients aged less than 50 years old had increased from 22.1% between 2013 till 2014 to 23.7% between 2015 till 2016 (Wan Ahmad, 2017b). Meanwhile, NCVD-ACS Registry Report in 2016 documented that approximately 25% of ACS admissions from 2014 to 2015 were patients aged less than 50 years old (Wan Ahmad, 2017a). Apparently, AMI remains a principal cause of deaths among male Malaysian adults (13.2%) in the

past five years as reported by the Department of Statistics Malaysia in 2017 (Health Fact Ministry of Health, 2017)

The diagnosis of AMI at a prime age during family and career establishment, leads to significant adverse effects on the physical well-being and mental state of the patients, their families and the community. Furthermore, AMI at young age is more prevalent in males, who are usually the main breadwinners for the families. AMI at this productive age contributes to a greater socioeconomic impact due to the loss of vital human capital, increased family financial burden and excessive usage of public health care facilities. It has been reported that approximately 15% of young patients were not able to return to work following AMI episode due to deterioration of health condition that compromised their performances at the workplace (Dreyer, Xu, Zhang, Du, Strait, Bierlein, et al., 2016).

In the light of significant health and economic burden of AMI in young adults, identification of those with a higher risk of developing CAD at a young age is crucial to improving disease preventative strategies. Undeniably, the traditional risk factors such as hypercholesterolemia, hypertension, smoking, diabetes and family history have important role in identifying those at high risk of developing CAD. However, the risk of CAD in young adults is usually underestimated, as the young age is considered as a main protective factor (Agostino et al., 2008; Lakatta & Levy, 2003). Therefore, with the increasing trend in the prevalence of premature AMI, additional biomarkers are required to improve the risk stratifications of CAD among young adults.

Apart of smoking that is found to be the most prevalent risk factor for young adults with AMI in general population, hypertension remains an important risk factor

among young Malaysian AMI patients (Hoo, Foo, Mohd, & Lim, 2016; Zuhdi et al., 2013). Unlike smoking which is an obvious high-risk behaviour, hypertension particularly in young adult is more challenging to be recognized due to lower level of health awareness in this age group (Abdul-razak, Daher, Ramli, Ariffin, Mazapuspavina, Ambiga, et al., 2016).

Consequently, young patient with the first episode of AMI was more likely to have untreated hypertension compared to the elderly AMI patients (OR: 2.99; 95% CI: 2.00-4.46,  $p < 0.001$ ) (Chan, Woo, Wong, Chia, Sutandar & Tan, 2006). Poor management of high blood pressure (BP) may lead to acceleration of CAD development. It has been shown that uncontrolled hypertension in young adult was associated with higher relative risks (RR) for CVD mortality than older hypertensive patients; RR: 4.1, 95% CI 3.7-4.6, RR: 2.6, 95% CI 2.4-2.9 and RR: 1.9, 95% CI 1.8-2.0 at ages 35-59, 60-69 and 70-79 years respectively (Lewington, Lacey, Clarke, Guo, Kong, Yang, et al., 2016).

Besides hypertension, there is increasing evidence that individuals with prehypertension (BP 120-139/80-89 mm Hg) is almost twice as likely to develop CVD as normotensive individuals (Huang, Wang, Cai, Mai, Hu, Tang & Xu, 2013). The risk of CVD is higher in individuals with Stage 2 prehypertension (BP 130-139/85-89) than those in Stage 1 prehypertension (BP 120-129/80-84 mm Hg) (Huang et al., 2013). Therefore, accurate CVD risk assessment and effective blood pressure control are not only crucial at hypertension stage, individuals with prehypertension should also be identified and managed accordingly to reduce the risk of CVD development.

Current management for hypertension with low CVD risk and prehypertension is risk factor modification as recommended by the Malaysia 5<sup>th</sup> Edition of Clinical

Practice Guideline for Management of Hypertension (2018). Unfortunately, risk factor modification strategies seem less likely to benefit the young people due to a false sense of good health, which cause delays in seeking medical advice and poor compliance (Hulsegge, Looman, Daviglius, Schouw, & Verschuren, 2016). A survey performed among 3501 young AMI patients showed that only half of patients believed that they were at risk of heart disease prior to the acute event (Leifheit-Limson, D'Onofrio, Daneshvar, Geda, Nueno, Spertus & Krumholz, 2015). These patients also had never discussed risk factors modification with their health care providers, despite nearly all of them having more than one risk factor, and 64% having more than three risk factors.

Apparently, CAD risk among young hypertensive and prehypertensive adults are commonly ineffectively assessed. Thus, the role of biological markers in identifying young adults who are at risk of CAD in these cohorts has grown in importance. The identification of CAD biomarkers among young adults with elevated blood pressure will improve predictive accuracy of CAD and enhance clinical decision for blood pressure management in the low CVD risk group.

High-sensitivity C-reactive protein (hs-CRP) is one of the most promising protein markers in predicting the occurrence of CAD in a clinical setting (Torres & Ridker, 2003; Wang, Tan, Han, Bai, He & Liu, 2017). However, hs-CRP is a general inflammatory marker, thus it is less specific as it may be elevated in other inflammatory reactions. Consequently in CAD, the use of multi-biomarkers approach was proposed to produce a more accurate predictive value, instead of depending on a single biomarker (Bogavac-stanojevic & Jelic, 2010).

The emergence of ‘omic’ technologies such as genomic, proteomic and metabolomics have allowed more research opportunities in the discovery of new CAD biomarkers. Of these, proteomic analysis is proposed to be the best method to study multifactorial disease such as CAD, which is a result of interactions between genetic abnormalities and environmental influences (Singh, Aikawa, & Aikawa, 2016). Protein is the main functional component in any cell or tissue. Thus, modifications in protein expression at various stages of the disease development are potential candidates for risk, diagnostic or prognostic markers.

CAD is a silent disease and the development of underlying atherosclerosis occurs many years prior to the acute presentation of AMI. Several pathophysiological mechanisms such as inflammation, lipid dysregulation, oxidative stress and coagulation have been proposed to play important roles in the establishment of atherosclerotic plaques (Ambrose & Singh, 2015). Each process is associated with different proteins expressions. Hence, investigation on the alterations of protein expression in diseased tissues may reflect the pathophysiological changes that occur, and lead to the discovery of novel biomarkers as well as therapeutic target proteins.

Plasma proteomic study specific to young AMI patients is essential to discover potential CAD biomarkers that could improve the risk stratification, diagnosis, and prognostication of the disease in younger population. Apart from predicting CAD in healthy individuals, the new biomarker might be utilized as a predictor of CAD in young prehypertensive and hypertensive adults. Such discovery is important to improve clinical decision for blood pressure control in young adults. Additionally, plasma proteomic study specific to young adults may help unearth the reason behind the acceleration of atherosclerotic process which leads to the early emergence of AMI.